Catalyst Funds Management Pty Ltd boosted its position in DaVita Inc. (NYSE:DVA - Free Report) by 77.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,800 shares of the company's stock after purchasing an additional 2,100 shares during the period. Catalyst Funds Management Pty Ltd's holdings in DaVita were worth $718,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Amundi raised its holdings in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. FMR LLC raised its stake in shares of DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company's stock valued at $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of DaVita by 256.8% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock worth $24,301,000 after purchasing an additional 116,758 shares during the period. Glenmede Trust Co. NA grew its stake in shares of DaVita by 731.6% in the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company's stock worth $20,207,000 after purchasing an additional 108,446 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after purchasing an additional 92,014 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.
DaVita Trading Down 0.5 %
DVA traded down $0.77 during trading on Thursday, hitting $149.06. The company's stock had a trading volume of 882,372 shares, compared to its average volume of 781,937. The firm has a market capitalization of $11.92 billion, a P/E ratio of 13.88, a PEG ratio of 1.07 and a beta of 0.99. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The stock's fifty day moving average price is $158.73 and its 200-day moving average price is $157.55. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on DVA shares. Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays increased their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, DaVita has an average rating of "Hold" and an average target price of $166.33.
Check Out Our Latest Stock Report on DaVita
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Stories
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
